The days between approval and the first patient actually receiving a therapy, measured market by market. Most launch measurement looks backward. This one looks forward, while there is still time to change the outcome.
A short series on why those days matter, what they cost, and why a shared way to measure them could change how launches are run.
of new therapy launches miss their first three years of revenue expectations.
the median wait from approval to patient access across Europe. Nearly a year and a half.
the difference in wait between the fastest and slowest European markets for the same class of medicine.
shared metric that could bring all of this into the open: Time to First Patient Access.
Sources: EFPIA Patients W.A.I.T. Indicator 2025, BrandLaunchX founding dataset.
We are building a shared benchmark for this measure, the TFPA Global Index, and shaping it with the people who run launches.